GSK sees sales slump due to COVID-19 disruption

28 April 2021

Sales and earnings were down at UK drugmaker GlaxoSmithKline (LSE: GSK) in the group’s first quarter 2021 financial results, albeit no worse than expected.

Turnover dropped 18% to £7.42 billion ($10.3 billion), caused partly by a 32% slump in sales in the Vaccines division, with governments prioritizing the rollout of COVID-19 jabs ahead of the likes of GSK’s Shingrix, revenue from which was down by nearly half. In the Pharmaceuticals unit, revenue fell 12% to £3.9 billion.

Total earnings per share (EPS) were £0.22, 32% lower than the same period last year but in line with expectations due to the anticipated impact of the pandemic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK